PT - JOURNAL ARTICLE AU - Moskov, Mikaela AU - Hedlund, Julia Lindberg AU - Popova, Svetlana AU - Lycke, Maria AU - Ivansson, Emma AU - Tolf, Anna AU - Gyllensten, Ulf AU - Sundfeldt, Karin AU - Stålberg, Karin AU - Enroth, Stefan TI - Deep plasma proteomics identifies and validates an eight-protein biomarker panel that separate benign from malignant tumors in ovarian cancer AID - 10.1101/2024.10.10.24315232 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.10.24315232 4099 - http://medrxiv.org/content/early/2024/10/10/2024.10.10.24315232.short 4100 - http://medrxiv.org/content/early/2024/10/10/2024.10.10.24315232.full AB - Ovarian cancer has the highest mortality of all gynecological cancers and in symptomatic women, surgery is commonly used as final diagnostic. Available literature indicates that women with benign tumors could often be conservatively managed but accurate molecular tests are needed for triaging where gold-standard imaging techniques are inconclusive or lacking. Here, we analyzed 5416 plasma proteins in two independent cohorts (N=171+233) with symptomatic women that have been surgically diagnosed with benign or malignant tumors. Using one cohort as discovery, we compared protein levels of benign tumors with early stage (I-II), late stage (III-IV) or any stage (I-IV) ovarian cancer. In this analysis, 327 associations, corresponding to 191 unique proteins, were identified out of which 326 (99.7%) replicated. The 191 proteins were compared with their corresponding tumor gene expression in the replication cohort and only 11% (21/191) were found to have significant correlation. Protein-protein correlation networks were generated and 62 of the 191 proteins were highly correlated with at least one other protein, suggesting that many of the observed associations could be secondary effects. Multivariate models were trained using the discovery cohort including a fixed cut-off for malignancy. In the replication cohort, an eight-protein model achieved an AUC of 0.96 corresponding to 97% sensitivity at 68% specificity. For early-stage tumors, the sensitivity was estimated at 91% at 68% specificity compared to 85% and 54% for CA-125 alone. Our results indicate that up to one third of benign cases could be identified by molecular measures thereby reducing the need for diagnostic surgery.One Sentence Summary Plasma proteomics for separation of benign and malignant tumors in ovarian cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Swedish Research Council, The Swedish Cancer Foundation and The Swedish state under the agreement between the Swedish government and the county council - the ALF-agreement. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Regional Ethics Committee in Uppsala (Dnr: 2016/145) and Göteborg (Dnr: 201-15) and informed written consent was obtained from all participants following the guidelines of the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.